Hengrui Pharmaceutical Co., Ltd. is a high-profile company in the pharmaceutical industry, and by analyzing its fundamental information in recent years, it can find some meaningful trends and changes.
First of all, from the perspective of net profit, Hengrui Pharmaceutical's performance in the past three years has generally grown steadily. Net profit from 2020 reached 632.8 billion, 45 in 2021300 million and 39 in 20220.6 billion, which indicates that the company has achieved considerable profitability in the past few years. However, the net profit for 2023 fell to 347.4 billion, a decrease compared with the previous three years.
The non-net profit data shows a similar trend. From 59 in 20206.1 billion grew to 42 in 20210.1 billion and 34. in 2022100 million, and then 33. in 20236 billion. This downward trend may be worth watching.
In terms of total operating income, Hengrui Pharmaceutical has had a relatively stable growth in recent years. From 277 in 20203.5 billion increased to 259 in 20210.6 billion and 212 in 20227.5 billion, and then 170 in 20231.4 billion. A steady increase in total operating income may mean that the company is becoming more competitive in the market.
The basic earnings per share indicator shows the level of a company's earnings per share. Between 2020 and 2023, basic earnings per share changed relatively little, from 099 down to 055。This shows that Hengrui Pharmaceutical has maintained a stable level in terms of earnings per share.
Another notable metric is return on equity. In recent years, Hengrui Pharmaceutical's return on equity has fluctuated between 8% and 14%. This indicator shows the company's ability to create value from its assets, and Hengrui Pharmaceutical's performance in this regard is encouraging.
In addition to financial metrics, it is also possible to focus on the company's liquidity and profitability. The current ratio and quick ratio show the company's solvency and liquidity position, and the values of both indicators show an increasing trend, which means that the company has sufficient ability to repay debt and meet short-term funding needs. The gearing ratio is within a reasonable range of about 6% to 11%.
To sum up, Hengrui Pharmaceutical's performance in recent years has been generally stable. Despite the decline in net profit and non-net profit, the company still maintains good profitability and growth ability. The stable performance of total operating income, basic earnings per share and return on equity shows the company's stable competitiveness in the market. Paying attention to the company's future development, especially in an environment of fierce market competition and policy changes, will help to better assess its potential investment value.